AstraZeneca

En tant que l’une des figures de proue du secteur pharmaceutique au Canada, AstraZeneca est fière d’accroître sa présence dans l’écosystème florissant des sciences de la vie en Ontario. Notre investissement de 820 millions $ CA en Ontario permettra la création de plus de 700 emplois et aidera à faire avancer la science afin d’offrir des médicaments novateurs pour diverses maladies, telles que le cancer de la prostate, du poumon et du sein, l’insuffisance rénale aiguë, la MPOC, l’amyloïdose et l’hypophosphatasie.   Nous remercions le Ontario Government | Gouvernement de l’Ontario de toujours être prêt à travailler avec nous au renforcement de la position de l’Ontario en tant que centre mondial des sciences de la vie et de l’innovation.

Our scientists in Oncology R&D are exploring a range of translational approaches to help extend the potential benefits of immunotherapy to more patients. From models that may better reflect human biology, to digital twins that help simulate treatment response, we’re aiming to advance a suite of translational approaches that could provide deeper mechanistic insights and help shape future combination strategies. Discover more in our latest article: https://lnkd.in/eT6qVxbJ #WhatScienceCanDo

As one of Canada’s leading pharmaceutical companies, we are proud to continue growing our presence in Ontario’s thriving life sciences ecosystem. Our C$820 million investment in Ontario is supporting the creation of 700+ jobs and help advance innovative medicines for such disease areas as Prostate, Lung and Breast Cancers, Acute Kidney Failure, COPD, Amyloidosis, and Hypophosphatasia.   Thank you to the Ontario Government | Gouvernement de l’Ontario for its ongoing support and partnership as we work together to strengthen Ontario’s position as a global hub for life sciences and innovation.

When a chest X-ray unexpectedly revealed a tumour in her left lung, Jan quickly learned how biomarker testing, such as testing for EGFR mutations, could help determine the best possible treatment for her specific cancer type. Lung cancer remains the leading cause of cancer death globally. At this year’s World Conference on Lung Cancer, stories like Jan’s serve as a clear reminder that early detection, biomarker testing at diagnosis and precision medicine can contribute to improved outcomes and longer-term survival. By identifying the specific genetic characteristics of a tumour early, clinical teams can match patients to targeted treatment strategies when it matters most. #WCLC26

Addressing inequity in lung health starts with understanding where care gaps exist and who is most impacted. A new Lung Health Equity Framework provides a consistent way to identify and measure this across COPD and lung cancer care pathways. Developed with input from an international advisory committee and policy experts from The London School of Economics and Political Science (LSE), this evidence-based resource can help inform targeted action – giving policy makers, health system leaders and advocates: · A shared set of equity indicators to pinpoint care gaps across COPD and lung cancer pathways · A way to identify underserved populations most impacted · A decision-making tool to direct resources where they can have the greatest impact Swipe through to see the key Framework policy recommendations for advancing lung health equity. #LungHealthEquity #LungHealth #HealthEquity The Lung Health Equity Framework has been developed by LCP Health and initiated and funded by AstraZeneca.

TIME has ranked us #5 out of 1,000 companies on the 2026 World’s Best Companies list, and #1 in our industry. Recognised for the fourth year in a row, we increased our scores across employee satisfaction, revenue growth and sustainability transparency. Thank you to our colleagues and partners, whose commitment and collaboration have made this possible. https://lnkd.in/evwqdFYq #WhatScienceCanDo #TIME #WorldsBestCompanies

For most people, taking a breath is something we don’t think about. But for nearly 500 million people living with respiratory diseases, the reality can be very different. We’re going deeper into the biology of respiratory disease to help transform outcomes for patients. In COPD, we’re building on our understanding of the disease to explore underlying drivers, including inflammation and mucus production, and open new possibilities to address persistent unmet need. As new science took centre stage at #ERS2026, our ambition is clear: to keep pushing the boundaries of what’s possible in respiratory medicine. Hear from our Global Head of R&D, Respiratory and Immunology, Caterina Brindicci, on how we’re helping shape the future of respiratory care: https://lnkd.in/eTU47zBG

The future of lung cancer care is being shaped today – through earlier diagnosis, improved access to care and more personalised treatment approaches enabled by technology and scientific innovation. As we head into WCLC 2026, our leaders share their vision for how continued scientific progress could transform what is possible by 2040, as we work towards our ambition to eliminate cancer as a cause of death. #WCLC26

Every hour, about 425 people will have died from COPD (chronic obstructive pulmonary disease). This is the cost of inaction. What if many of these deaths could be prevented? Would you Speak Up for change? Timely diagnosis, equitable access to guideline-recommended treatment, continuity of care, and stronger prevention policies can improve outcomes for people living with COPD and help reduce avoidable hospitalisations and deaths. That's why the Speak Up for COPD coalition has launched a new Joint Declaration, calling for evidence-based policy action to improve COPD care around the world. Every voice matters. Add yours by signing the Joint Declaration today: https://lnkd.in/eaeFnAmZ #SpeakUpForCOPD #ERS

Congratulations to Health Systems Trust and PATH – the 2025 Powering Breast Cancer Progress grant recipients! These initiatives will help improve access to timely breast cancer diagnosis and optimal management for underserved patient populations in South Africa and Rwanda respectively. These important programmes will also build evidence on the value of patient navigation services to inform and improve outcomes for patients. Find out more here: https://lnkd.in/eFp-vk9P #PoweringBreastCancerProgress